What is the market price forecast for filgotinib in 2025?

Filgotinib (Filgotinib) is a new generation JAK1 selective inhibitor that has been approved for marketing in many countries such as Europe, the United States and Japan. It is mainly suitable for the treatment of moderate to severe active rheumatoid arthritis. It has good therapeutic prospects, especially for patients who have insufficient response to traditional DMARDs (disease-modifying antirheumatic drugs). With the widespread use of JAK inhibitor drugs in the treatment of rheumatic immune diseases, filgotinib has gradually become an important new member of the global anti-rheumatic drug market.

Currently, filgotinib has not yet been officially launched in mainland China, so it is not included in domestic medical insurance and does not have a unified market retail price. However, in overseas markets, such as the European Union, Japan and other places, the original version of the drug has been widely sold. The common specification is 200mg*30 tablets, and the price per box ranges from RMB 10,000 to 15,000, depending on factors such as the country of sale, tax policy, and medical insurance reimbursement. Due to exchange rate fluctuations and different import channels, this price may also have certain fluctuations.

At the same time, some countries have launched generic versions of filgotinib. For example, pharmaceutical companies in Laos and other places have successfully developed generic drugs with the same ingredients, usually 100mg*30 tablets, and the price per box is only between 900 and 1,500 yuan. This price is significantly lower than the original drug, providing more choices for patients with limited budgets. Generic drugs are basically the same as the original drugs in terms of ingredients, dosage and efficacy, but when purchasing, you need to pay attention to choosing formal channels to ensure the quality and safety of the drugs.

Looking to the future, as China's drug approval system reform continues to advance, filgotinib is expected to be introduced into the domestic market at an accelerated pace. Once approved for marketing, if it can be successfully included in the national medical insurance directory, its market pricing may drop significantly, improving patient accessibility and treatment compliance.

Reference materials:https://go.drugbank.com/drugs/DB14845